Breakthrough in Food Allergy Treatment: Low-Dose Immunotherapy Shows Promise

Strategic Insights -

Research from Clinical Research Center for Allergy and Rheumatology has shed light on the potential of low-dose oral immunotherapy (OIT) in treating food allergies. According to the study, low-dose OIT has demonstrated efficacy in desensitizing patients to various food allergens, including milk, eggs, wheat, and peanuts. The treatment has shown improved safety profiles compared to conventional higher-dose approaches, with reduced rates of severe adverse reactions. Long-term follow-up studies have also shown progressively improving sustained unresponsiveness (SU) rates and a decrease in adverse events over time.

Key Takeaways:

  • Low-dose oral immunotherapy (OIT) has been developed to address safety concerns associated with conventional high-dose protocols for treating food allergies.
  • Clinical trials have reported sustained unresponsiveness (SU) achievements of 33-50% for milk, up to 71% for eggs, 25-37.5% for wheat, and 33-74% for peanut allergies after low-dose OIT treatment.
  • The treatment has shown improved safety profiles compared to conventional higher-dose approaches, with substantially reduced rates of severe adverse reactions.
  • Long-term follow-up studies of up to 6 years have shown progressively improving SU rates and a decrease in adverse events over time.
  • Critical factors for successful low-dose OIT implementation include appropriate patient selection based on age, risk stratification, and individual clinical characteristics.
  • Integration with biological agents such as omalizumab may further enhance safety and efficacy in selected high-risk patients.
  • Careful patient selection remains essential to optimize treatment outcomes and minimize risks.

Statistics:

  • 6-8% of children worldwide suffer from food allergies.
  • 33-50% of patients achieved sustained unresponsiveness (SU) to milk allergies after low-dose OIT.
  • Up to 71% of patients achieved SU to egg allergies.
  • 25-37.5% of patients achieved SU to wheat allergies.
  • 33-74% of patients achieved SU to peanut allergies.
  • Severe adverse reactions were reduced by low-dose OIT compared to conventional higher-dose approaches.
  • Long-term follow-up studies showed progressively improving SU rates and a decrease in adverse events over time.

Sources:

  • Clinical Research Center for Allergy and Rheumatology, "Findings on Food Allergies Reported by Researchers at Clinical Research Center for Allergy and Rheumatology (Recent Advances in Oral Immunotherapy for Food Allergies)," Clinical Trials Week, October 27, 2025.
  • Recent Advances in Oral Immunotherapy for Food Allergies, Clinical Reviews in Allergy & Immunology, 2025;68(1):89.
  • Humana Press Inc, 999 Riverview Drive Suite 208, Totowa, NJ 07512, USA.